Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-CALM: Suvecaltamide for Essential Tremor
NCT03101241Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Countries
- 1
- Sponsor
- Jazz Pharmaceuticals plc
- Modality
- Small Molecules
- Drugs
- suvecaltamide
- Conditions
- essential tremor (ET)
01
Overview
Phase 2, randomised, double-blind trial in essential tremor (ET) comparing CX-8998 with Placebo (2 arms). Primary endpoint: The Essential Tremor Rating Assessment Scale Performance Subscale Total Score at Day 28. Started Aug 2017; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
CX-8998
Suvecaltamide titrated to 10 mg BID
Placebo
Matching Placebo
03
Who it enrols
Adults 18-75 with definite or probable essential tremor, TETRAS score >= 15, and tremor severity >= 2. One concomitant anti-tremor med allowed (except primidone).
04
Endpoints
Primary
The Essential Tremor Rating Assessment Scale Performance Subscale Total Score
Secondary
The Essential Tremor Rating Assessment Scale Activities of Daily Living Subscale Score
Kinesia ONE Score
Beyond the preview
Go deeper on NCT03101241.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101241.